There's more to these small biotechs than just their coronavirus vaccine programs.
News & Analysis: VBI Vaccines
A company's vaccine manufacturing capabilities can make a world of difference.
Momentum continued from an upgrade and investors' attraction to stocks with COVID-19 programs.
Bad news about rising COVID-19 cases is good news for these stocks.
The company hopes to file for FDA approval of its hepatitis B vaccine this year.
The vaccine developer was forced to raise cash at a relatively low offering price, which will result in a significant amount of dilution.
Investors piled in to COVID-19 vaccine plays today. Here's why.
Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.)